306 of those were excluded because they did not have GBM. The counting really starts at 1293.
250 of those had recurrence/progression events before treatment with DCVax-l. This was not initially designed as a recurrent trial, so the counting actually starts at 1043.
121 patients declined to enter the trial before leukapheresis. So the counting actually starts at 922 patients.
Another 40 withdrew consent. So the counting actually starts at 882.
Another 35 did not have surgery. So the counting actually starts at 847.
41 died or fell off the Karnofsky performance status before DCVax-l treatment could start. So the counting actually starts at 806.
91 had deviations from standard chemoradiation protocol, history of prior malignancy, inadequate renal or bone marrow function, etc, so the counting actually starts at 715.
75 patients did not have placebo and/or
DCVax-l manufactured for them. So the counting actually starts at 640.
61 patients did not have successful leukapheresis. So the counting actually starts at 579.
Of those 579,
201 did not have sufficient tumor size to make lysate. 35 were excluded due to investigator decision and 12 for other reason.
331 entered the trial.
News 
Market Data 
Discover 
AI
